Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study

The aim of this phase I study is to evaluate, for the first time, the safety and efficacy of sintilimab in pediatric patients diagnosed with advanced or recurrent malignancies. During the dose escalation phase, patients received a single intravenous infusion of sintilimab at varying doses of 1, 3, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Que, Yi, Wang, Juan, Sun, Feifei, Wang, Shan, Zhu, Jia, Huang, Junting, Zhao, Zhenzhen, Zhang, Li, Liu, Juan, Xu, Jiaqian, Zhen, Zijun, Sun, Xiaofei, Lu, Suying, Zhang, Yizhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570390/
https://www.ncbi.nlm.nih.gov/pubmed/37828033
http://dx.doi.org/10.1038/s41392-023-01636-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570390/
https://www.ncbi.nlm.nih.gov/pubmed/37828033
http://dx.doi.org/10.1038/s41392-023-01636-9

Ejemplares similares